Karo Bio's next act

Karo Bio AB thinks its deal with Pfizer Inc. will change the common perception that the company has nothing of value but eprotirome.

Eprotirome, a thyroid hormone receptor agonist, is in the Phase III AKKA trial in 630 patients with heterozygous familial hypercholesterolemia (HeFH). Interim three-month data from the first 150 patients are expected in 2Q12...